Deprescribing long-term use of benzodiazepines in primary care practice: where to next?
SLEEP · 2023
DOI: 10.1093/sleep/zsad015 ↗Kurz gefasst
Editorial in der Zeitschrift SLEEP, 2023. Verfasst von Alexander Sweetman und 3 weiteren Autor:innen. Beteiligte Einrichtung: The Adelaide Institute for Sleep Health: A Centre of Research Excellence, College of Medicine and Public Health, Flinders University, Adelaide, Austr…. Hauptthemen laut MEDLINE: Deprescriptions, Sleep Initiation and Maintenance Disorders. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Globally, insomnia management guidelines now mandate that benzodiazepine (BDZ)/benzodiazepine receptor agonist (BZRA) use is limited to short-term periods (up to four weeks) [1]. Patients are provided evidence-based non-pharmacological behavioral treatments such as cognitive behavioral treatment for insomnia (CBTi), and when prescribing occurs, plans are put in place to deimplement, deprescribe, or discontinue use after the recommended period using recommended tapering guidelines. Clinicians are increasingly turning to initiate BDZ/BZRA prescriptions with caution, in a phenomenon referred to as “reluctant pharmaceuticalization,” [2] but often use this resort in the face of the patient, practice, or systemic barriers. The problem remains that there are significant numbers of long-term benzodiazepine users in communities/institutionalized care settings who continue benzodiazepine use despite not deriving clinically meaningful sleep-related benefits from the medication and yet being exposed to a significant likelihood of experiencing harmful adverse effects [1]. There is increasing recognition that deprescribing or discontinuation of BDZ/BZRAs in long-term users requires more than a stepped reduction in a dose—given the issue of dependence, beliefs about the “need” for the medicine to help sleep, and reduced self-efficacy which need to be addressed through psychological approaches. BDZ/BZRA discontinuation trials are increasing including CBTi as a tool to aid the process [3, 4]. Primary care, where much of the prescribing of benzodiazepines and other sedatives occurs, remains the key point for initiating and supporting the discontinuation process. Examples of studies investigating the effect of CBTi interventions on sedative-hypnotic use in the primary care setting are showcased in Table 1 below. Therapist-delivered and interactive digital CBTi programs delivered concurrently with sedative-hypnotic tapering programs have also been shown to improve insomnia and facilitate sedative-hypnotic cessation in various settings and patient groups [5, 6]. Effect of CBTi administered in primary care on sedative-hypnotic use The term “sedative hypnotics” is used to encompass any medications consumed for sleep. *Researcher-defined “sedative-hypnotic reduction” outcome. Effect of CBTi administered in primary care on sedative-hypnotic use The term “sedative hypnotics” is used to encompass any medications consumed for sleep. *Researcher-defined “sedative-hypnotic reduction” outcome. The study by Coteur et al [7]. aimed to assess whether the addition of an interactive e-learning program based on the principles of CBTi to usual care by a general practitioner (referred to by the study authors as “blended care”) would increase rates of discontinuation of BDZ/BZRA after 12 months in patients using long term BDZ/BZRA. This trial, which was conducted within the primary care setting in Belgium to address this important research question has several strengths including its multi-center, pragmatic, cluster-randomized, and controlled study design. Study investigators recruited a total of 99 general practitioners who were working in one of 86 primary care practice clusters and involved close to 1000 patients on long-term BDZ/BZRA (i.e. a minimum of 6 months of daily BZD/BZRA use prior to study entry) into the trial. BDZ/BZRA users could access the e-learning component on their own as they chose. Furthermore, BDZ/BZRA usage at study commencement and each of the follow-up time points was objectively confirmed using toxicological screening of urine samples, rather than relying on patient self-report. It is unclear whether patients were using BDZ/BZRAs continuously or intermittently during the study. BDZ/BZRA discontinuation rates were low (19%–20%) and there were no differences between intervention and usual care groups [7]. This is disappointing given prior studies have demonstrated CBTi is effective and reduces BDZ/BZRA usage when used in primary care settings [5]. Given CBTi is dynamic and multi-faceted, future research is encouraged to include detailed information on the CBTi components used to derive the efficacy of CBTi and its components, compared to sleep education alone, in this context. It is important to note that general practitioners in both the intervention and control arms of the study [7] received an education, which may have diluted the effect of the blended intervention. This study [7] highlights the importance of developing and refining interventions to assist different groups of patients with insomnia symptoms and chronic sedative-hypnotic dependence. There is an increasing investment in primary care trials to improve access to CBTi and reduce reliance on pharmacotherapy for insomnia, for example in Australian Primary Care [8, 9]. Given this heavy investment into researching service models and interventions that can successfully lead to the discontinuation of sedative/hypnotics in long-term users, it may be time to consider important facets of what is known about medication use behaviors in BDZ/BZRA users. In deprescribing trials, starting with strategies that motivate individuals to make the change towards not using their sedatives/hypnotics may be an important step. Many patients often have low-risk perceptions about their benzodiazepine use, for example, as shown in a point-of-purchase survey of 75 benzodiazepine users in community pharmacies (Sydney, Australia) [10]. Thus, tailoring interventions to channel patients’ own risk perceptions could be an effective strategy when initiating benzodiazepine deprescribing [10, 11]. In the trial reported by Coteur et al [7]., there appeared to be a baseline set of 3%–8% of patients who discontinued even prior to randomization, where even an invitation to participate in the trial was sufficient motivation to discontinue. Furthermore, in their assessment of benzodiazepine dependency [12], Coteur et al [7]. reported that many trial participants were aware of benzodiazepine use is “problematic” but had not progressed from awareness to action [10]. Health psychological Interventions, such as effective risk perception assessment and risk communication strategies to enhance this “pool” of patients motivated to discontinue may have enhanced the effectiveness of the blended care intervention reported by Coteur et al [7, 13, 14]. Indeed, Allary et al., have reported that psychological predictors for patient discontinuation are often neglected in deprescribing trials—and addressing issues such as enhancing self-efficacy/self-perceived competence in patients should be an important preliminary step [15]. It is also important to focus on patients’ health access patterns. Whilst prescription of benzodiazepines and deprescribing need to take place in primary care physician settings, patients may have a range of health venues they frequently access. Community pharmacies (retail pharmacies) are one of the common access points for patients worldwide; pharmacists have expertise in deprescribing and have a significant opportunity to discuss medication use with patients. There are many examples of trials using pharmacist-led deprescribing for benzodiazepines within multidisciplinary teams. The EMPOWER trial [16–19], for example, utilized pharmacies to identify long-term benzodiazepine users from prescription databases and then mailed identified consumers in the intervention group a well-designed and described informational brochure. At 6 months, 62% of these consumers initiated a conversation with their pharmacist about discontinuation, 27% had discontinued, and 11% reduced their dose in a significant difference from to control group [16–19]. In the Australian Reducing Use of Sedatives trial, which was a longitudinal prospective intervention trial involving 150 aged care homes and 12 157 aged care home residents, multi-component intervention strategies were used [20] with dispensed history reviews for aged care patients, aged care staff education and involving prescribers to action deprescribing, resulting in a 40% discontinuation or dose reduction rate in aged care home residents [20]. In Australia, where many pharmacies provide sleep health services [21], pharmacists have demonstrated a willingness to participate in deprescribing work and upskill themselves in sleep health care provision [22, 23]. It may be suggested that successful deprescribing trials for sedatives in people with sleep disorders require complex interventions that target individuals, their various health professionals and health system/health policy levels. An important step in designing or testing such interventions should include careful consideration of health psychological frameworks that motivate individuals to action change (patients and health professionals) and involve multiple healthcare venues, that benzodiazepine users access frequently. Financial disclosure: None. Nonfinancial disclosure: AS, NL, and CLCC report research funds from the National Health and Medical Research Council, Flinders University, Flinders Foundation, ResMed, Philips Respironics, Sleepio (Big Health), and The Hospital Research Foundation. AS has commissioned work for the Australian Doctor Group and SleepReviewMag. BS reports sponsored work by TEVA. NL reports funding the Department of Defence. All disclosures are outside the scope of the current publication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Adelaide Institute for Sleep Health: A Centre of Research Excellence, College of Medicine and Public Health, Flinders University, Adelaide, Australia.
- National Centre for Sleep Health Services Research: A NHMRC Centre of Research Excellence, Flinders University, Adelaide, Australia.
- Respiratory and Sleep Service, Southern Adelaide Local Health Network, SA Health, Adelaide, Australia.
- School of Pharmacy, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
- CIRUS, Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, University of Sydney, Sydney, Australia.
ORCID-Profile: Alexander Sweetman, Nicole Lovato
Zitieren
APA
Sweetman, A., Lovato, N., Li Chai-Coetzer, C., & Saini, B. (2023). Deprescribing long-term use of benzodiazepines in primary care practice: where to next?. SLEEP. https://doi.org/10.1093/sleep/zsad015
Vancouver
Sweetman A, Lovato N, Li Chai-Coetzer C, Saini B. Deprescribing long-term use of benzodiazepines in primary care practice: where to next?. SLEEP. 2023. doi:10.1093/sleep/zsad015
BibTeX
@article{Sweetman2023,
author = {Sweetman, Alexander and Lovato, Nicole and Li Chai-Coetzer, Ching and Saini, Bandana},
title = {Deprescribing long-term use of benzodiazepines in primary care practice: where to next?},
journal = {SLEEP},
year = {2023},
doi = {10.1093/sleep/zsad015}
}
EUVIMED